Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
about
Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzymeIdentification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human plateletsPirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failureTemporal and spatial expression of tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1 and -2) in the bovine corpus luteumTissue inhibitors of metalloproteinasesTargeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitorsHigh resolution structure of the N-terminal domain of tissue inhibitor of metalloproteinases-2 and characterization of its interaction site with matrix metalloproteinase-3Utilization of a novel recombinant myoglobin fusion protein expression system to characterize the tissue inhibitor of metalloproteinase (TIMP)-4 and TIMP-2 C-terminal domain and tails by mutagenesis. The importance of acidic residues in binding theTissue inhibitor of metalloproteinases-4 (TIMP-4) gene expression is increased in human osteoarthritic femoral head cartilageSpecific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2Identification and characterization of a novel member of the fibroblast growth factor familyA phase II trial of marimastat in advanced pancreatic cancerTIMP-2 is required for efficient activation of proMMP-2 in vivoLocalization and expression of tissue inhibitor of metalloproteinase-4 in the immature gonadotropin-stimulated and adult rat ovaryMaintenance of a Protein Structure in the Dynamic Evolution of TIMPs over 600 Million YearsDiastolic dysfunction and heart failure with a preserved ejection fraction: Relevance in critical illness and anaesthesiaMetalloproteinases and tissue inhibitors of metalloproteinases.Matrix metalloproteinases and their inhibitors in tumour growth and invasion.Engineering of selective TIMPs.Matrix metalloproteinase inhibition. From the Jurassic to the third millennium.The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer.Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in miceMatrix metalloproteinases in tumour invasion and metastasis.Role of gelatinases MMP-2 and MMP-9 in tissue remodeling following acute lung injury.Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy.Expression level and glycan dynamics determine the net effects of TIMP-1 on cancer progressionMyocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium.Proteinase activity regulation by glycosaminoglycans.Complex roles of tissue inhibitors of metalloproteinases in cancer.Proteolytic events of wound-healing--coordinated interactions among matrix metalloproteinases (MMPs), integrins, and extracellular matrix molecules.Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?Tetraspanin CD9 promotes the invasive phenotype of human fibrosarcoma cells via upregulation of matrix metalloproteinase-9.Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patientsAtaxia telangiectasia mutated kinase plays a protective role in β-adrenergic receptor-stimulated cardiac myocyte apoptosis and myocardial remodeling.Metalloproteinase in myocardial adaptation and maladaptation.Deficiency of ataxia telangiectasia mutated kinase modulates cardiac remodeling following myocardial infarction: involvement in fibrosis and apoptosis.Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction.Matrix metalloproteinases and their inhibitors in gastric cancer.Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.Serum levels of tissue inhibitors of metalloproteinase 2 in patients with systemic sclerosis with duration more than 2 years: correlation with cardiac and pulmonary abnormalities.
P2860
Q22254090-FAF7EA90-C655-4925-9256-72905E4CBB11Q24672897-E97AB25A-7E74-49A9-AEE4-DA6890BE719EQ24684669-FEED8BBF-D960-4D6E-930C-0A9BE3A88122Q24796638-B866AD9D-E26A-4E42-BB56-5F9BB7869857Q26829539-02C03197-3023-40B6-B60F-E435FE9131E6Q26830555-E1B9AB18-D216-40BA-91B3-945FAA229A34Q27765120-DA972816-0E59-49C5-8A68-137855BDA624Q28206603-07F7BAF4-E7AB-4BD7-8A2C-E8513ACF7317Q28214460-1B0E9DD3-C001-4B2F-B339-7727E2DB7241Q28240574-B04D76BC-858A-45E1-9C16-07AF3F8F851BQ28283605-AC77862B-4370-41AA-B9B2-7417DD632CF1Q28366568-3F7CB7B2-B9CD-4170-8176-52EF2E2F68FDQ28512714-5BE023A8-F9B4-4E1F-8DD2-89D443D9D8E3Q28570779-A2DF5E36-CBB6-40FF-BDD6-F2EA84956963Q30385426-2E61C460-3B49-4BB8-A881-34FE538641D1Q30450624-CB38C0EE-0CB6-4BF5-9107-2FC11BFA9D7CQ33538435-D001D6FD-85B5-4CAA-9384-3BE8A8C5AACDQ33603385-3963CEED-8F32-4470-8191-866849A42B1EQ33692887-DA99E63F-F0AE-459B-B6FF-D947F85EC612Q33692943-8725041C-D702-49CD-9900-F145CA769A30Q33693020-C1B1A129-97ED-43A9-8CE2-2BA9B57CCA0FQ33696289-CCF1380F-F4F4-448B-ACB9-056DF563491CQ33765792-9C8D9358-4693-481A-BF37-588417F43E0AQ33958573-A9D84C9F-14F9-4D78-B894-FA231EC64084Q34296764-148CCBE6-AC39-491B-86A2-FC715EE9E305Q34314043-2ACB26D5-34DA-4564-8D43-2C1E5AA5DB45Q34510788-34F842B8-6189-442E-82E7-F3853FB08283Q34533127-2AD67E51-51C1-4D46-8B43-BE4BFDA80811Q34596110-AB839472-C55E-4118-AFE0-E43C4CE6BB59Q34632691-67E3B0E7-7AF7-47C6-8CAC-9F19240161DBQ34768858-4D4F2D68-1608-44D2-BFFD-919C7CE4E3FDQ34808021-92E15931-0FD5-4606-8831-5705E2549DB6Q34894487-F018EFA6-D743-40C9-83FA-7F8ED461AF1DQ35019405-8199304B-17B5-4A45-BD02-350BF13D32B0Q35030016-43663E9E-171E-4B41-AA71-524FDE133741Q35073104-C45DE347-D52B-475E-942A-CE22E35402C4Q35103051-F2FC4459-0CDE-481D-8477-9E39BF892ECBQ35353488-2B3FFFA1-F303-41DF-A70D-900C2EEA268FQ35549401-23544BD8-E9AB-4B92-89D9-A94DB03419D1Q35598573-0677238B-821C-4F9D-9953-5B6F041B5D2A
P2860
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
description
1996 nî lūn-bûn
@nan
1996 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@ast
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@en
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@en-gb
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@nl
type
label
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@ast
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@en
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@en-gb
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@nl
prefLabel
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@ast
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@en
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@en-gb
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@nl
P2093
P2860
P3181
P356
P1476
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
@en
P2093
P2860
P304
P3181
P356
10.1074/JBC.271.48.30375
P407
P577
1996-11-29T00:00:00Z